Suppr超能文献

Respimat(®)软雾™吸入器的研发及其在呼吸系统疾病中的临床应用。

Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders.

作者信息

Dalby Richard N, Eicher Joachim, Zierenberg Bernd

机构信息

Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD, USA.

出版信息

Med Devices (Auckl). 2011;4:145-55. doi: 10.2147/MDER.S7409. Epub 2011 Sep 1.

Abstract

The Respimat(®) Soft Mist™ Inhaler (SMI) (Boehringer Ingelheim International GmbH, Ingelheim, Germany) was developed in response to the need for a pocket-sized device that can generate a single-breath, inhalable aerosol from a drug solution using a patient-independent, reproducible, and environmentally friendly energy supply. This paper describes the design and evolution of this innovative device from a laboratory concept model and the challenges that were overcome during its development and scaleup to mass production. A key technical breakthrough was the uniblock, a component combining filters and nozzles and made of silicon and glass, through which drug solution is forced using mechanical power. This allows two converging jets of solution to collide at a controlled angle, generating a fine aerosol of inhalable droplets. The mechanical energy comes from a spring which is tensioned by twisting the base of the device before use. Additional features of the Respimat(®) SMI include a dose indicator and a lockout mechanism to avoid the problems of tailing-off of dose size seen with pressurized metered dose inhalers. The Respimat(®) SMI aerosol cloud has a unique range of technical properties. The high fine particle fraction allied with the low velocity and long generation time of the aerosol translate into a higher fraction of the emitted dose being deposited in the lungs compared with aerosols from pressurized metered dose inhalers and dry powder inhalers. These advantages are realized in clinical trials in adults and children with obstructive lung diseases, which have shown that the efficacy and safety of a pressurized metered dose inhaler formulation of a combination bronchodilator can be matched by a Respimat(®) SMI formulation containing only one half or one quarter of the dose delivered by a pressurized metered dose inhaler. Patient satisfaction with the Respimat(®) SMI is high, and the long duration of the spray is of potential benefit to patients who have difficulty in coordinating inhalation with drug release.

摘要

Respimat(®)软雾吸入器(SMI)(德国英格海姆勃林格殷格翰国际有限公司)的研发是为了满足对一种便携式设备的需求,该设备能够利用独立于患者、可重复且环保的能源供应,从药物溶液中产生单呼吸可吸入气雾剂。本文描述了这种创新设备从实验室概念模型的设计与演变,以及在其开发和扩大规模至大规模生产过程中克服的挑战。一项关键技术突破是一体成型部件,它由硅和玻璃制成,将过滤器和喷嘴结合在一起,通过机械动力迫使药物溶液通过。这使得两股汇聚的溶液射流以可控角度碰撞,产生可吸入液滴的细微气雾剂。机械能来自一个弹簧,在使用前通过扭转设备底部来张紧弹簧。Respimat(®)SMI的其他特性包括剂量指示器和锁定机制,以避免出现与压力定量吸入器相关的剂量大小逐渐减少的问题。Respimat(®)SMI气雾剂云具有一系列独特的技术特性。与压力定量吸入器和干粉吸入器产生的气雾剂相比,高细颗粒分数、低速度和气雾剂的长产生时间使得更高比例的释放剂量沉积在肺部。这些优势在患有阻塞性肺病的成人和儿童的临床试验中得到体现,试验表明,一种联合支气管扩张剂的压力定量吸入器制剂的疗效和安全性,可由一种Respimat(®)SMI制剂与之匹配,而该制剂所含剂量仅为压力定量吸入器给药剂量的二分之一或四分之一。患者对Respimat(®)SMI的满意度很高,喷雾的长时间持续对那些在协调吸入与药物释放方面有困难的患者可能有益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3f9/3417885/d8e64d11d0c3/mder-4-145f1.jpg

相似文献

1
Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders.
Med Devices (Auckl). 2011;4:145-55. doi: 10.2147/MDER.S7409. Epub 2011 Sep 1.
2
Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler.
Int J Chron Obstruct Pulmon Dis. 2009;4:381-90. doi: 10.2147/copd.s3391. Epub 2009 Oct 19.
3
A review of the development of Respimat Soft Mist Inhaler.
Int J Pharm. 2004 Sep 28;283(1-2):1-9. doi: 10.1016/j.ijpharm.2004.06.018.
4
The Respimat Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients.
Clin Drug Investig. 2019 Nov;39(11):1021-1030. doi: 10.1007/s40261-019-00835-z.
8
Clinical implications of the tiotropium/olodaterol inhaler for patients with chronic obstructive pulmonary disease.
Postgrad Med. 2018 Aug;130(6):515-522. doi: 10.1080/00325481.2018.1481713. Epub 2018 Jul 4.
9
In vitro tests for aerosol deposition. III: effect of inhaler insertion angle on aerosol deposition.
J Aerosol Med Pulm Drug Deliv. 2013 Jun;26(3):145-56. doi: 10.1089/jamp.2012.0989. Epub 2012 Oct 1.
10
[Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].
Rev Mal Respir. 2010 Dec;27(10):1141-9. doi: 10.1016/j.rmr.2010.10.024. Epub 2010 Nov 18.

引用本文的文献

1
Prediction of the Atomization Process in Respimat Soft Mist Inhalers Using a Volume of Fluid-to-Discrete Phase Model.
Bioengineering (Basel). 2025 Mar 6;12(3):264. doi: 10.3390/bioengineering12030264.
2
Scale-Up and Postapproval Changes in Orally Inhaled Drug Products: Scientific and Regulatory Considerations.
J Aerosol Med Pulm Drug Deliv. 2025 Apr;38(2):39-63. doi: 10.1089/jamp.2024.0036. Epub 2024 Dec 9.
4
Research Progress on Liposome Pulmonary Delivery of Nucleic Acid Vaccine and Its Mechanism of Action.
J Aerosol Med Pulm Drug Deliv. 2024 Oct;37(5):284-298. doi: 10.1089/jamp.2023.0025. Epub 2024 Apr 26.
5
Aerosol Plumes of Inhalers Used in COPD.
Pulm Ther. 2024 Mar;10(1):109-122. doi: 10.1007/s41030-023-00249-5. Epub 2024 Jan 9.
6
Repurposing mucosal delivery devices for live attenuated tuberculosis vaccines.
Front Immunol. 2023 Mar 30;14:1159084. doi: 10.3389/fimmu.2023.1159084. eCollection 2023.
7
A four-part guide to lung immunology: Invasion, inflammation, immunity, and intervention.
Front Immunol. 2023 Mar 31;14:1119564. doi: 10.3389/fimmu.2023.1119564. eCollection 2023.
8
Pulmonary drug delivery for acute respiratory distress syndrome.
Pulm Pharmacol Ther. 2023 Apr;79:102196. doi: 10.1016/j.pupt.2023.102196. Epub 2023 Jan 20.
10
Impact of Sex on Proper Use of Inhaler Devices in Asthma and COPD: A Systematic Review and Meta-Analysis.
Pharmaceutics. 2022 Jul 28;14(8):1565. doi: 10.3390/pharmaceutics14081565.

本文引用的文献

1
Asthma patients prefer Respimat Soft Mist Inhaler to Turbuhaler.
Int J Chron Obstruct Pulmon Dis. 2009;4:225-32. doi: 10.2147/copd.s3452. Epub 2009 Jun 11.
6
7
Development and validation of a patient satisfaction and preference questionnaire for inhalation devices.
Treat Respir Med. 2005;4(1):41-52. doi: 10.2165/00151829-200504010-00005.
8
A review of the development of Respimat Soft Mist Inhaler.
Int J Pharm. 2004 Sep 28;283(1-2):1-9. doi: 10.1016/j.ijpharm.2004.06.018.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验